NCT06974968View on ClinicalTrials.gov

Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 25, 2028

Primary Completion Date

May 25, 2031

Study Completion Date

May 26, 2031

Conditions
Spinal Cord InjurySafetyEfficacyClinical TrialInduced Pluripotent Stem CellsHuman Motor Neuron ProgenitorTransplantationRCT
Interventions
BIOLOGICAL

Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells

"Description:~XS228 Cell Injection is an investigational, allogeneic cell therapy product composed of motor neuron progenitor cells (MNPCs) derived from human induced pluripotent stem cells (iPSCs). This advanced therapy medicinal product (ATMP) is being developed for the treatment of spinal cord injury (SCI) and represents a novel approach in regenerative medicine."

OTHER

Placebo

Standard rehabilitation protocols

Trial Locations (1)

510630

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
collaborator

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

INDUSTRY

lead

Third Affiliated Hospital, Sun Yat-Sen University

OTHER